Holen Sie sich die Stockscreener-App
175.10
3.07%
-5.54
Handel nachbörslich:
175.50
0.40
+0.23%
Schlusskurs vom Vortag:
$180.64
Offen:
$176.11
24-Stunden-Volumen:
354.34K
Relative Volume:
27.55
Marktkapitalisierung:
$18.65B
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+0.00%
1M Leistung:
+0.00%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$175.00
$180.40
1-Wochen-Bereich:
$175.00
$184.76
52-Wochen-Spanne:
$175.00
$184.76
Beigene Ltd Adr Stock (ONC) Company Profile
Firmenname
Beigene Ltd Adr
Sektor
Branche
Telefon
13459494123
Adresse
C/O MOURANT GOVERNANCE SERVICES (CAYMAN), GRAND CAYMAN
Vergleichen Sie ONC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ONC
Beigene Ltd Adr
|
175.10 | 18.65B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.32 | 105.15B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
730.30 | 80.25B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
648.62 | 38.79B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.95 | 30.43B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
126.88 | 30.42B | 3.30B | -501.07M | 1.03B | -2.1146 |
Beigene Ltd Adr Stock (ONC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2024-09-18 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-02-06 | Fortgesetzt | JP Morgan | Overweight |
| 2023-09-12 | Eingeleitet | Macquarie | Outperform |
| 2023-08-17 | Eingeleitet | Jefferies | Buy |
| 2023-07-17 | Eingeleitet | Citigroup | Buy |
| 2023-06-30 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2023-01-12 | Eingeleitet | Daiwa Securities | Buy |
| 2022-10-13 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-10-13 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-08-09 | Fortgesetzt | JP Morgan | Overweight |
| 2022-03-17 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-02-07 | Eingeleitet | Deutsche Bank | Buy |
| 2021-10-12 | Eingeleitet | Bernstein | Outperform |
| 2021-10-06 | Hochstufung | CLSA | Underperform → Buy |
| 2021-03-08 | Eingeleitet | China Renaissance | Buy |
| 2021-03-01 | Herabstufung | CLSA | Outperform → Underperform |
| 2020-11-09 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2020-11-06 | Herabstufung | Maxim Group | Buy → Hold |
| 2020-11-06 | Herabstufung | Piper Sandler | Neutral → Underweight |
Alle ansehen
Beigene Ltd Adr Aktie (ONC) Neueste Nachrichten
(NASDAQ:BGNE) Stock Quotes, Forecast and News Summary - Benzinga
FDA approves BeiGene's TEVIMBRA for advanced gastric cancer treatment - Investing.com
Weekly Upgrades and Downgrades - InvestorPlace
BeiGene shares reiterate Buy rating on robust oncology pipeline - Investing.com
Beigene directors sell shares worth $194.2 million - Investing.com
10 High Growth Healthcare Stocks to Invest in Now - Insider Monkey
10 Biggest Biotechnology Companies - Investopedia
BeiGene announces passing of board member Donald Glazer - Investing.com
BeiGene stock momentum builds on Brukinsa success, says JPMorgan's Fye - Investing.com
BeiGene CEO John Oyler sells shares worth over $3.75 million - Investing.com
BeiGene's SVP sells shares worth nearly $285k - Investing.com
BeiGene executive sells over $1.1m in company shares - Investing.com
CCBI Lowers BEIGENE (06160.HK) TP to $140, Solid 2Q Results Expected - AASTOCKS.com
Nomura Raises BEIGENE (06160.HK)'s TP to $158.37 and Rev. Forecast for FY24/FY25 - AASTOCKS.com
BeiGene's (BGNE) Shares Surge 32% in a Month: Here's Why - Yahoo Finance
Primecap Odyssey Funds' 2023 Semiannual Letter - GuruFocus.com
Making it harder to "buy" China, Inc. - US-China Institute
What Happens to Your ETFs if Chinese ADRs Delist? - HK.Morningstar.com
Will We See a Slew of ADR Delistings? - HK.Morningstar.com
See What the Public Investment Fund Bought Recently Including Walmart and FedEx Stocks - Sovereign Wealth Fund Institute
BeiGene (BGNE) Gets FDA Nod for Brukinsa Label Expansion - Yahoo Finance
BeiGene Ltd. Sponsored ADR to Host Earnings Call - AccessWire
Finanzdaten der Beigene Ltd Adr-Aktie (ONC)
Es liegen keine Finanzdaten für Beigene Ltd Adr (ONC) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
11.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):